Alembic Limited
Others · NSE
↑ 42.5% vs fair value
52W Low
₹70
+24.2% from low
52W High
₹126
-30.3% from high
Valuation Gauge
Current Price
₹88
Fair Value
₹152
Fair Value Analysis
₹152
Based on free cash flow projections and balance sheet strength analysis and earnings growth potential for Others sector companies | Sector-cheap: P/E at 11th percentile vs sector peers. | CAUTION: ROCE declining (latest 4.0%) — returns on capital are falling; verify this isn't a value trap.
Cash Flow Analysis
33% weight
Balance Sheet Value
33% weight
Growth Valuation
33% weight
Price vs Market
Shareholding Pattern
Stock Health Score
Financially Strong
Profitability
ROE of 12.5% is acceptable for Others sector (benchmark: 15%)
Debt & Leverage
D/E ratio of 0.0x is well within the Others sector norm of 0.8x — strong balance sheet
Valuation vs Peers
P/E of 7.2x trades at a 82% discount to Others sector median (40x) — attractively valued
Cash Flow
FCF margin of 16.9% — exceptional cash generation (₹36 Cr)
Earnings Growth
5yr EPS CAGR of 11.8% is below the Others sector average of 12.0%
Dividend
Dividend yield of 2.7% provides strong shareholder returns (benchmark: 1.5%)
Company Health Timeline
10-year financial health at a glance
Sentiment Trend — Last 30 Days
Historical Returns
Key Ratios & Growth
FCF Yield
2.6%
Free cash flow / market cap
Revenue Growth (YoY)
+27.6%
Year-on-year revenue change
Profit Growth (YoY)
-7.7%
Year-on-year PAT change
Operating Cash Flow
₹86 Cr
TTM cash from operations
Key Financials
EPS (TTM)
₹12.4
P/E Ratio
7.2x
P/B Ratio
0.9x
ROE
12.5%
ROCE
6.6%
Debt / Equity
0.01x
Beta
0.71
Div Yield
2.7%
FCF (Cr)
₹36 Cr
Revenue (Cr)
₹211 Cr
EPS Growth 5Y
11.8%
Mkt Cap (Cr)
₹2,310 Cr
52W High
₹125.5
52W Low
₹70.5
Book Value/Share
₹98.9
Financial History
| Period | Revenue | Op Profit | OPM% | PAT | EPS |
|---|---|---|---|---|---|
| TTM | ₹240 Cr | ₹98 Cr | 41.0% | ₹319 Cr | ₹12.41 |
| 2025-03-31 | ₹222 Cr | ₹94 Cr | 42.0% | ₹311 Cr | ₹12.10 |
| 2024-03-31 | ₹157 Cr | ₹57 Cr | 36.0% | ₹269 Cr | ₹10.46 |
| 2023-03-31 | ₹127 Cr | ₹40 Cr | 32.0% | ₹191 Cr | ₹7.42 |
| 2022-03-31 | ₹78 Cr | ₹14 Cr | 18.0% | ₹222 Cr | ₹8.65 |
| 2021-03-31 | ₹74 Cr | ₹11 Cr | 15.0% | ₹343 Cr | ₹13.35 |
| 2020-03-31 | ₹74 Cr | ₹3 Cr | 4.0% | ₹329 Cr | ₹12.82 |
| 2019-03-31 | ₹124 Cr | ₹18 Cr | 15.0% | ₹213 Cr | ₹8.30 |
| 2018-03-31 | ₹125 Cr | ₹11 Cr | 9.0% | ₹163 Cr | ₹6.10 |
| 2017-03-31 | ₹147 Cr | ₹7 Cr | 5.0% | ₹145 Cr | ₹5.45 |
| 2016-03-31 | ₹134 Cr | ₹6 Cr | 5.0% | ₹235 Cr | ₹8.78 |
| 2015-03-31 | ₹144 Cr | ₹10 Cr | 7.0% | ₹107 Cr | ₹3.99 |
| 2010-03-31 | ₹1.1K Cr | ₹103 Cr | 9.0% | ₹40 Cr | ₹1.48 |
Compounded Growth Rates
Sales Growth
Profit Growth
EPS Growth
Peer Comparison
Others| Stock | Price | Fair Value | MoS% | P/E | ROE | Signal |
|---|---|---|---|---|---|---|
AVRO INDIA LIMITED | ₹10.3 | ₹75.8 | +86.5% | 38.2 | — | UNDERVALUED |
Magnum Ventures Limited | ₹19.8 | ₹119.4 | +83.4% | — | -1.6% | UNDERVALUED |
DCM Shriram Industries Limited | ₹41.7 | ₹196.1 | +78.7% | 3 | 12.6% | UNDERVALUED |
Star Paper Mills Limited | ₹141.5 | ₹657.4 | +78.5% | 5.6 | 44.2% | UNDERVALUED |
HB Stockholdings Limited | ₹60.5 | ₹281.1 | +78.5% | 3.8 | 13.1% | UNDERVALUED |
Balkrishna Paper Mills Limited | ₹18.7 | ₹80.6 | +76.8% | 3.1 | 26.1% | UNDERVALUED |
Heads UP Ventures Limited | ₹7.1 | ₹28.8 | +75.3% | 3.9 | — | UNDERVALUED |
Credo Brands Marketing Limited | ₹88.5 | ₹305.8 | +71.1% | 10.9 | 16.4% | UNDERVALUED |
Institutional Activity
Bulk deals, block deals, short selling & delivery volume — NSE data
Insider Trading
Share this Stock
Download card · Share on WhatsApp
Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant
What is Dalal Street saying?
r/IndiaInvestments · r/Dalal_Street_Investments · r/IndianStockMarket
No Reddit mentions found yet for ALEMBICLTD.
StockTwits
What traders are saying right now
No StockTwits activity found for ALEMBICLTD.
Telegram Channels
ET Markets · CNBC TV18 · Moneycontrol · Zee Business · NDTV Profit
No Telegram mentions found yet for ALEMBICLTD.
Search Interest
Google Trends · India · Last 90 days
Trend data not yet available — check back soon.
Alembic Limited Board Meeting Scheduled for May 19 to Consider Q4FY26 Results - scanx.trade
Alembic Pharmaceuticals shares jump 14% on USFDA approval for cancer drug - MSN
Alembic Ltd is Rated Sell - Markets Mojo
Stocks in news: Wipro, HUL, Angel One, Alembic Pharma, HDFC Life - MSN
Stocks in news: Wipro, HUL, Angel One, Alembic Pharma, HDFC Life - MSN
Stocks in news: Wipro, HUL, Angel One, Alembic Pharma, HDFC Life - MSN
Stocks in news: Wipro, HUL, Angel One, Alembic Pharma, HDFC Life - MSN
Alembic Pharma gains after incorporating subsidiary in Philippines - Business Standard